Deucravacitinib in Japanese patients with moderate to severe PP, GPP, or EP: A phase III trial
skin.substack.com
Today's report also covers efficacy and safety of piclidenoson, identification of psoriatic arthritis in patients with psoriasis, and more (1,900 words, 8 minutes, 30 seconds)
Deucravacitinib in Japanese patients with moderate to severe PP, GPP, or EP: A phase III trial
Deucravacitinib in Japanese patients with…
Deucravacitinib in Japanese patients with moderate to severe PP, GPP, or EP: A phase III trial
Today's report also covers efficacy and safety of piclidenoson, identification of psoriatic arthritis in patients with psoriasis, and more (1,900 words, 8 minutes, 30 seconds)